Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Pemetrexed 13Carboplatin 13Docetaxel 11Cisplatin 11pembrolizumab 9Paclitaxel 8Gemcitabine 7Erlotinib Hydrochloride 4Bevacizumab 4anlotinib 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Gefitinib 3Dexamethasone 3dexamethasone acetate 2dexamethasone 21-phosphate 2cobimetinib 2cemiplimab 2auricularum 2atezolizumab 2apatinib 2Vemurafenib 2Surgical Procedures, Operative 2Standard of Care 2Specimen Handling 2Ramucirumab 2Calcium Dobesilate 2trametinib 1toripalimab 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Carcinoma, Non-Small-Cell Lung × Pharmacogenomic Testing × Clear all
NCT01208064 2018-07-12

Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2/3 Terminated
102 enrolled
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡